Pfizer’s CEO says the FDA could approve the company’s updated COVID-19 booster shots by the end of the month.
Aug. 2, 2023 -- Pfizer and Moderna asked the FDA in June to approve a new version of their boosters aimed at the XBB.1.5 subvariant, which started spreading widely in the winter. That was right after the FDA advised them to update the shots against XBB.1.5 before the fall booster efforts.says. A related strain, XBB.1.16, accounts for about 15%.
FDA advisers have said there won’t be much difference in effectiveness against the strains because they are so similar.COVID hospitalizations are rising in the United States and are expected to continue to increase as cooler seasons approach. Hospitalizations are still lower than at any point during the pandemic, NBC reported.NBC said it isn’t known whether the boosters will be recommended for everyone in the country. The CDC will decide that, probably after the FDA authorizes the shots.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer mulls cost cuts on volatile COVID products demandPfizer will launch a cost-cutting program if demand for its COVID-19 products keeps underperforming expectations this fall, the U.S. drugmaker said on Tuesday, after quarterly sales for the vaccine and pill fell short of Wall Street targets.
Baca lebih lajut »
Updated Covid boosters could be authorized by end of month, Pfizer saysThe FDA could authorize Pfizer's updated Covid boosters by the end of August, Pfizer CEO Albert Bourla said during an investor call.
Baca lebih lajut »
FDA, DEA call on drugmakers to boost manufacturing amid ongoing shortage of prescription stimulants | CNNAmid an ongoing shortage of prescription stimulants in the US, federal agencies are calling on drugmakers to boost manufacturing and on health care providers to closely monitor prescribing practices.
Baca lebih lajut »
Thousands of Tydemy birth control pills recalled, may be ineffective, FDA warnsA drugmaker recalled thousands of birth control pills after testing found they might have lower effectiveness.
Baca lebih lajut »
FDA, DEA Blame Demand, Drug Makers for ADHD Med ShortageIn a letter to the public the FDA and the DEA contend that unprecedented demand, potential overprescribing, and underproduction are the primary reasons for the national shortage of stimulants to treat ADHD.
Baca lebih lajut »
Thousands of birth control pills recalled, may be ineffective, FDA warnsA total of 4,179 boxes of Tydemy brand birth control pills have been recalled, which amounts to about 350,000 tablets that might be less effective at stopping pregnancy.
Baca lebih lajut »